BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37885116)

  • 21. Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group.
    Dubois SG; Geier E; Batra V; Yee SW; Neuhaus J; Segal M; Martinez D; Pawel B; Yanik G; Naranjo A; London WB; Kreissman S; Baker D; Attiyeh E; Hogarty MD; Maris JM; Giacomini K; Matthay KK
    Int J Mol Imaging; 2012; 2012():250834. PubMed ID: 23050139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
    Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
    J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells.
    Bayer M; Kuçi Z; Schömig E; Gründemann D; Dittmann H; Handgretinger R; Bruchelt G
    Nucl Med Biol; 2009 Apr; 36(3):287-94. PubMed ID: 19324274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma.
    Anongpornjossakul Y; Sriwatcharin W; Thamnirat K; Chamroonrat W; Kositwattanarerk A; Utamakul C; Sritara C; Chokesuwattanasakul P; Thokanit NS; Pakakasama S; Anurathapan U; Pongphitcha P; Chotipanich C; Hongeng S
    Nucl Med Commun; 2020 Apr; 41(4):336-343. PubMed ID: 31939898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Meta-iodobenzylguanidine-Based Copper Thiosemicarbazide-1-guanidinomethylbenzyl Anticancer Compounds Targeting Norepinephrine Transporter in Neuroblastoma.
    Zhang H; Xie F; Cheng M; Peng F
    J Med Chem; 2019 Aug; 62(15):6985-6991. PubMed ID: 31283215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter.
    Pifl C; Reither H; Hornykiewicz O
    Eur J Pharmacol; 2015 May; 755():119-26. PubMed ID: 25771452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.
    Johnson K; McGlynn B; Saggio J; Baniewicz D; Zhuang H; Maris JM; Mosse YP
    Pediatr Blood Cancer; 2011 Dec; 57(7):1124-9. PubMed ID: 21495159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose
    Kayano D; Wakabayashi H; Nakajima K; Kuroda R; Watanabe S; Inaki A; Toratani A; Akatani N; Yamase T; Kunita Y; Hiromasa T; Takata A; Mori H; Saito S; Araki R; Taki J; Kinuya S
    Ann Nucl Med; 2020 Jun; 34(6):397-406. PubMed ID: 32219730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome.
    Shalaby-Rana E; Majd M; Andrich MP; Movassaghi N
    Clin Nucl Med; 1997 May; 22(5):315-9. PubMed ID: 9152532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression.
    Lode HN; Bruchelt G; Seitz G; Gebhardt S; Gekeler V; Niethammer D; Beck J
    Eur J Cancer; 1995; 31A(4):586-90. PubMed ID: 7576974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
    McCluskey AG; Boyd M; Ross SC; Cosimo E; Clark AM; Angerson WJ; Gaze MN; Mairs RJ
    Clin Cancer Res; 2005 Nov; 11(21):7929-37. PubMed ID: 16278418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma.
    DuBois SG; Matthay KK
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):53-65. PubMed ID: 23474635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
    French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
    Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anatomic patterns of relapse and progression following treatment with
    Fishel Ben Kenan R; Polishchuk AL; Hawkins RA; Braunstein SE; Matthay KK; DuBois SG; Haas-Kogan DA
    Pediatr Blood Cancer; 2022 Feb; 69(2):e29396. PubMed ID: 34662499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (
    Grand-Guillaume J; Mansi R; Gaonkar RH; Zanger S; Fani M; Eugster PJ; Beck Popovic M; Grouzmann E; Abid K
    J Transl Med; 2023 Sep; 21(1):604. PubMed ID: 37679770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Residual meta-iodobenzyl guanidine (MIBG) positivity following therapy for metastatic neuroblastoma: Patient characteristics, imaging, and outcome.
    Usmani N; Deyell RJ; Portwine C; Rafael MS; Moorehead PC; Shammas A; Vali R; Farfan M; Vanniyasingam T; Morgenstern DA; Irwin MS
    Pediatr Blood Cancer; 2021 Dec; 68(12):e29289. PubMed ID: 34411405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.
    Villablanca JG; Ji L; Shapira-Lewinson A; Marachelian A; Shimada H; Hawkins RA; Pampaloni M; Lai H; Goodarzian F; Sposto R; Park JR; Matthay KK
    Pediatr Blood Cancer; 2018 May; 65(5):e26940. PubMed ID: 29350464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.
    DuBois SG; Groshen S; Park JR; Haas-Kogan DA; Yang X; Geier E; Chen E; Giacomini K; Weiss B; Cohn SL; Granger MM; Yanik GA; Hawkins R; Courtier J; Jackson H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Villablanca JG; Marachelian A; Matthay KK
    Clin Cancer Res; 2015 Jun; 21(12):2715-21. PubMed ID: 25695691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripheral oxytocin treatment affects the rat adreno-medullary catecholamine content modulating expression of vesicular monoamine transporter 2.
    Jovanovic P; Spasojevic N; Stefanovic B; Bozovic N; Jasnic N; Djordjevic J; Dronjak S
    Peptides; 2014 Jan; 51():110-4. PubMed ID: 24239562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.
    Carlin S; Mairs RJ; McCluskey AG; Tweddle DA; Sprigg A; Estlin C; Board J; George RE; Ellershaw C; Pearson AD; Lunec J; Montaldo PG; Ponzoni M; van Eck-Smit BL; Hoefnagel CA; van den Brug MD; Tytgat GA; Caron HN
    Clin Cancer Res; 2003 Aug; 9(9):3338-44. PubMed ID: 12960120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.